PERNETTA –A non comparative randomized open label phase II trial of pertuzumab(P) + trastuzumab(T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2 positive metastatic breast cancer (SAKK 22/10 / UNICANCER UC-0140/1207).
J. Huober, P. Weder, C. Veyret, B. Thürlimann, et al.
 |
POSTER |
Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks.
A. Müller, A.J. Templeton, S. Hayoz, H. Hawle, et al.
|
POSTER |
TAILORED AXILLARY SURGERY WITH OR WITHOUT AXILLARY LYMPH NODE DISSECTION FOLLOWED BY RADIOTHERAPY IN PATIENTS WITH CLINICALLY NODE-POSITIVE BREAST CANCER (TAXIS): A MULTICENTER RANDOMIZED PHASE-III TRIAL.
Henke G, Knauer M, Ribi K, Hayoz S, et al.
|
POSTER |